Dr George D. Yancopoulos, Regeneron’s chief scientific officer, said: “We are honoured that the Galien Foundation has recognised Inmazeb […] Our ability to rapidly respond to Ebola was based ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Who Are the Key Players in the Inmazeb Market? .A leading company in the Inmazeb market is Regeneron Pharmaceuticals Inc. .The market remains highly competitive, with companies focusing on ...

In January, Regeneron announced preliminary data showing the medicine ... Stahl and his team had come up with the first-ever FDA-approved treatment for the illness. Inmazeb consists of three ...

Regeneron Pharmaceuticals ... Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process ...